Choose country
For healthcare professionals
Sign up for vaccine updates

We Focus On This

So They Can Focus
On That

For healthcare professionals
Sign up for vaccine updates
Novavax has 10+ years of vaccine development & innovation that has led us to today.
Where
we've been
Where
we are
Where
we're going

Where We've Been

We've been developing innovative investigational vaccines for years. We started with research into viruses like:

SARS

MERS

Novavax_Microsite_RSV_Icon_White

RSV

Novavax has 10+ years of vaccine development & innovation that has led us to today.
Where
we've been
Where
we are
Where
we're going

Where We Are

Our innovation continues with current investigational vaccines in trials for:

COVID-19

FLU

MALARIA

Novavax has 10+ years of vaccine development & innovation that has led us to today.
Where
we've been
Where
we are
Where
we're going

Where We're Going

As the world changes, we're working to change with it. We are working on investigational vaccines as COVID-19 evolves:

COVID-19 Variant-Specific

COVID-19 Booster

COVID-19 and Flu Combo

WE ARE ALSO CONTINUING TO STUDY AND DEVELOP INVESTIGATIONAL VACCINES AGAINST EMERGING STRAINS USING VARIANT-SPECIFIC APPROACHES

We are a biotechnology company solely devoted to innovating vaccine technology.
Our
Commitment
Built for the
real world
globe

Setting up the world for success in immunisation

COMMITTED TO ADVANCING IMMUNITY

We understand that we are only protected if we are all protected. That’s why throughout our history we’ve focused on the most urgent public health threats. Conducting studies intended to demonstrate efficacy and safety for regulatory authorities’ review requires diligence and time. We continue to do everything to ensure that every governmental guideline is met for our investigational vaccines.

We are a biotechnology company solely devoted to innovating vaccine technology.
Our
Commitment
Built for the
real world
globe

Built for the real world

  • We are developing investigational vaccines with ease of storage and transportation in mind

  • Proprietary technology allows for rapid creation and large-scale production of our investigational vaccines

Ready to pivot to respond to emerging viruses.
Proven
Technology
Improved
Stability
Enhanced
Immunity
Adaptability
and Efficiency

Building on generations of
research to deliver:

Tried and True Technology

  • At Novavax, our investigational vaccines are built on protein subunit vaccine technology, a well-known and established platform for creating effective vaccines, used for diseases such as seasonal flu, HPV, hepatitis B and Haemophilus influenzae type B

  • This platform can stimulate an immune response without exposure to the actual virus

Ready to pivot to respond to emerging viruses.
Proven
Technology
Improved
Stability
Enhanced
Immunity
Adaptability
and Efficiency

Innovating Proven Platforms
to Provide:

Improved Stability

  • Once we have identified and developed a recombinant protein, our nanoparticle vaccine technology helps stabilise the proteins

  • This approach is intended to help promote a robust immune response with the aim of producing strong and durable protection

Ready to pivot to respond to emerging viruses.
Proven
Technology
Improved
Stability
Enhanced
Immunity
Adaptability
and Efficiency

Evolving vaccine technology
to provide:

Enhanced Immunity

  • Adjuvants have been used for over 100 years to enhance the efficacy and durability of the body’s immune response

  • slide-3-3-2

    Our proprietary adjuvant, which includes a naturally derived saponin ingredient extracted from the bark of the Quillaja saponaria Molina tree, was developed with the goal of stimulating an enhanced immune response

Ready to pivot to respond to emerging viruses.
Proven
Technology
Improved
Stability
Enhanced
Immunity
Adaptability
and Efficiency

Choosing the right components
to help ensure:

Adaptability and Efficiency

  • slide-3-4-1

    Our nanoparticle technology allows us to quickly engineer the vaccine antigen to help control the impact of new variants

  • Adjuvants may allow use of a lower amount of antigen to help achieve a desired immune response. This may allow more doses to be produced

  • Investigational vaccines built on our platform can be efficiently produced and scaled to meet global demand

STAY INFORMED ON OUR VACCINE DEVELOPMENT

Just fill in the fields below, and we’ll keep you in the know with our latest news. All fields are required unless otherwise noted.

 

 

 

 

 

 

 

Your personal information will be used solely for the purpose of Novavax to contact you by email with helpful information on Novavax treatments, products, and services. Your personal information will be kept confidential and not distributed to third parties. You have the right to inspect, change, or delete this information by contacting [email protected].

You may opt out of these emails by selecting the 'unsubscribe' link included in our emails.

For more information about our privacy practices, including how we store and process your information, please review our privacy statement.
CAPTCHA